Plavix®
Clopidogrel is a thienopyridine antiplatelet agent that irreversibly inhibits the P2Y12 ADP receptor on platelets, reducing thrombotic events.
| Dosage Form | Oral Tablet (Film-Coated) |
| Strength | 75 mg, 300 mg |
| Storage | Store at 25°C. |
| Category | Cardiovascular |
| Availability | Available for Transfer |
Reduction of atherothrombotic events in recent MI/stroke, established PAD, or ACS (with aspirin).
Prodrug requiring hepatic CYP2C19 activation. The active metabolite irreversibly blocks the P2Y12 ADP receptor on platelet surface, inhibiting ADP-mediated platelet activation and aggregation.
Each Burrard Pharmaceuticals technology transfer package for Clopidogrel includes comprehensive documentation and support:
Complete formulation with manufacturing parameters, excipient specifications, and process controls.
Validated methods for assay, impurities, dissolution, and stability-indicating analysis.
Market-ready regulatory dossier templates — available through Burrard Intelligence subscription.
ICH-compliant stability studies (accelerated and long-term) with detailed protocols.
Scale-up procedures, batch records, equipment specifications, and in-process controls.
Direct advisory access to formulation scientists and regulatory specialists throughout transfer.
Our team can deliver the complete know-how package within 2–21 business days. Book a consultation to discuss your specific requirements.